NTRK1 and cancer: Oncogenic KRAS signaling is among the most prevalent drivers in human cancer, yet durable pathway suppression has historically been limited by incomplete target coverage, toxicity constraints for downstream kinase inhibitors, and rapid adaptive rewiring through receptor tyrosine kinase (RTK) feedback.